To include your compound in the COVID-19 Resource Center, submit it here.

Cytokinetics falls on Phase III ALS readout for tirasemtiv

Cytokinetics Inc. (NASDAQ:CYTK) fell $2.85 (26%) to $8.25 on Tuesday after the company said it will suspend development of tirasemtiv as the candidate missed the primary and secondary endpoints in the Phase III VITALITY-ALS trial to treat

Read the full 370 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE